Palisade Bio Offers Up To 2.06M Common Stock Shares At $2.43 Per Share

Benzinga03:26

Palisade Bio To Present PALI-2108 Data At 8th Annual Antifibrotic Drug Development Summit

BenzingaNov 21 21:16

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

GlobeNewswireNov 21 21:15

Brookline Capital Initiates Coverage On Palisade Bio With Buy Rating, Announces Price Target of $38

BenzingaNov 21 06:00 · Ratings

Palisade Bio Analyst Ratings

BenzingaNov 14 00:27 · Ratings

Maxim Group Maintains Palisade Bio(PALI.US) With Buy Rating, Cuts Target Price to $8

Futu NewsNov 13 21:36 · Ratings